Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Aditya Bardia(Harvard University), Leif W. Ellisen(Harvard University), Rachel O. Abelman(Massachusetts General Hospital), Jeffrey Peppercorn(Durham University), Veerle Bossuyt(Harvard University), Maria Shellock(Harvard University), Beverly Moy(Massachusetts General Hospital), Laura M. Spring(Massachusetts General Hospital), Bogang Wu(George Washington University), Sheng Sun(Harvard University), Seth A. Wander(Massachusetts General Hospital), Ann H. Partridge, Phoebe Ryan(Harvard University), Nayana Thimmiah(Harvard University), Aiko Nagayama(Harvard University), James T. Coates(Harvard University), Sara M. Tolaney(Dana-Farber Cancer Institute), Brenda Lormil(Harvard University), Dejan Juric(Massachusetts General Hospital), Victoria Attaya(Harvard University), Mark N. Melkonyan(Harvard University), Heather A. Parsons(Harvard University), Steven J. Isakoff(Harvard University)
Cited by 43
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene
|Nature Genetics|1993|1.4k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k